Berndt Modig, Pharvaris CEO
August 22, 2022 11:16 AM EDTUpdated August 23, 01:46 PM
FDA+

Phar­varis hits a snag with hered­i­tary an­gioede­ma pill as FDA places hold on tri­als

Aayushi Pratap

News Reporter

Swiss biotech Phar­varis an­nounced Mon­day that the FDA has placed a hold on the clin­i­cal tri­als for its oral drug PHA121 which aims at treat­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Chi­nese drug­mak­er re­ceives FDA warn­ing let­ter af­ter man­age­ment hin­dered in­spec­tion

GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

J&J, Pro­tag­o­nist re­veal two Phase 3 wins for oral IL-23 drug that's ex­pect­ed to be a block­buster

Mer­ck fi­nal­ly has sub­cu­ta­neous Keytru­da re­sults, and it's go­ing to reg­u­la­tors

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times